不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>Oxygen Biotherapeutics研发中心迁移至南卡罗来纳州

Oxygen Biotherapeutics研发中心迁移至南卡罗来纳州

Oxygen Biotherapeutics2012年8月30日 10:02 点击:1178

美国Oxygen Biotherapeutics

Oxygen Biotherapeutics宣布,研发部门从加州迁移至南卡罗来纳州,公司成功转租Costa Mesa大楼。

 

Oxygen Biotherapeutics Relocating R&D Function to North Carolina from California

MORRISVILLE, N.C.--(BUSINESS WIRE)--Aug. 28, 2012-- Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) announced today that it is searching for laboratory space in the Research Triangle Park region of North Carolina. Beginning in September, the company will be consolidating its operations and relocating its research and development function to North Carolina from Costa Mesa, CA. In making the announcement, the company reported that it successfully subleased its Costa Mesa facility at terms that made the transition cost effective.

“North Carolina has the business climate, facilities and creative talent we need to help push our programs forward. Relocating R&D to North Carolina has been under consideration for quite some time however, the recession strongly impacted the real estate market in southern California thereby preventing us from subletting the facility and making the transition sooner. We are excited about bringing this important function closer to our headquarters,” said Michael Jebsen, President and Chief Financial Officer.

OBI has engaged commercial real estate brokers to identify a new laboratory location. Three positions in California were eliminated due to the relocation and the company expects to replace these vacancies when the new facility is established. Current R&D activities allow for this transition period since most development work has been completed for the existing programs and all of the manufacturing of the company’s perfluorocarbon-based products – primarily Oxycyte® and Dermacyte® – is done by contract manufacturers.

不用本金就能赚钱的方法“The foundation of this company was built primarily on research that came out of our Costa Mesa lab, and we wish to thank all our California-based employees for their efforts over the years,” added Jebsen. “They have given us novel perfluorocarbon-based products and it is now our challenge to move them through the clinical stages to commercialization.”

About Oxygen Biotherapeutics, Inc.

不用本金就能赚钱的方法Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte® line of skin care cosmetics for the anti-aging market.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include the expansion of development of the Oxycyte and DERMACYTE product lines, the timing of the introduction of those new products, stockholder approval of the December 2011 financing, the closing of the additional installment of such financing, and the progress of our research programs, including clinical testing. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current reports on Form 10-Q and Form-10K. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Source: Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President
Corporate Communications
& Investor Relations

(来源: Oxygen Biotherapeutics )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

不用本金就能赚钱的方法 BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图